Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Olfactory dysfunction in LRRK2 G2019S mutation carriers.

Saunders-Pullman R, Stanley K, Wang C, San Luciano M, Shanker V, Hunt A, Severt L, Raymond D, Ozelius LJ, Lipton RB, Bressman SB.

Neurology. 2011 Jul 26;77(4):319-24. doi: 10.1212/WNL.0b013e318227041c. Epub 2011 Jul 13.

2.

Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.

Silveira-Moriyama L, Guedes LC, Kingsbury A, Ayling H, Shaw K, Barbosa ER, Bonifati V, Quinn NP, Abou-Sleiman P, Wood NW, Petrie A, Sampaio C, Ferreira JJ, Holton J, Revesz T, Lees AJ.

Neurology. 2008 Sep 23;71(13):1021-6. doi: 10.1212/01.wnl.0000326575.20829.45.

PMID:
18809839
3.

Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.

Gaig C, Vilas D, Infante J, Sierra M, García-Gorostiaga I, Buongiorno M, Ezquerra M, Martí MJ, Valldeoriola F, Aguilar M, Calopa M, Hernandez-Vara J, Tolosa E.

PLoS One. 2014 Oct 17;9(10):e108982. doi: 10.1371/journal.pone.0108982. eCollection 2014.

4.

Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers.

Marras C, Schüle B, Munhoz RP, Rogaeva E, Langston JW, Kasten M, Meaney C, Klein C, Wadia PM, Lim SY, Chuang RS, Zadikof C, Steeves T, Prakash KM, de Bie RM, Adeli G, Thomsen T, Johansen KK, Teive HA, Asante A, Reginold W, Lang AE.

Neurology. 2011 Jul 26;77(4):325-33. doi: 10.1212/WNL.0b013e318227042d. Epub 2011 Jul 13. Erratum in: Neurology. 2011 Oct 11;77(15):1501. Schuele, B [corrected to Schüle, B].

5.

Olfactory heterogeneity in LRRK2 related Parkinsonism.

Silveira-Moriyama L, Munhoz RP, de J Carvalho M, Raskin S, Rogaeva E, de C Aguiar P, Bressan RA, Felicio AC, Barsottini OG, Andrade LA, Chien HF, Bonifati V, Barbosa ER, Teive HA, Lees AJ.

Mov Disord. 2010 Dec 15;25(16):2879-83. doi: 10.1002/mds.23325.

PMID:
20818658
6.

Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease.

Kertelge L, Brüggemann N, Schmidt A, Tadic V, Wisse C, Dankert S, Drude L, van der Vegt J, Siebner H, Pawlack H, Pramstaller PP, Behrens MI, Ramirez A, Reichel D, Buhmann C, Hagenah J, Klein C, Lohmann K, Kasten M.

Mov Disord. 2010 Nov 15;25(15):2665-9. doi: 10.1002/mds.23272.

PMID:
20721915
7.

Olfactory dysfunction in sporadic Parkinson's Disease and LRRK2 carriers.

Johansen KK, Warø BJ, Aasly JO.

Acta Neurol Scand. 2014 May;129(5):300-6. doi: 10.1111/ane.12172. Epub 2013 Aug 13.

PMID:
23937295
8.

Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?

Saunders-Pullman R, Mirelman A, Wang C, Alcalay RN, San Luciano M, Ortega R, Raymond D, Mejia-Santana H, Ozelius L, Clark L, Orr-Utreger A, Marder K, Giladi N, Bressman SB.

Ann Clin Transl Neurol. 2014 Sep;1(9):670-8. doi: 10.1002/acn3.95. Epub 2014 Sep 30.

9.

Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.

Ruiz-Martínez J, Gorostidi A, Goyenechea E, Alzualde A, Poza JJ, Rodríguez F, Bergareche A, Moreno F, López de Munain A, Martí Massó JF.

Mov Disord. 2011 Sep;26(11):2026-31. doi: 10.1002/mds.23773. Epub 2011 May 24.

PMID:
21611983
10.

Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.

Sierra M, Sánchez-Juan P, Martínez-Rodríguez MI, González-Aramburu I, García-Gorostiaga I, Quirce MR, Palacio E, Carril JM, Berciano J, Combarros O, Infante J.

Neurology. 2013 Feb 12;80(7):621-6. doi: 10.1212/WNL.0b013e31828250d6. Epub 2013 Jan 16.

PMID:
23325906
11.

Subclinical signs in LRRK2 mutation carriers.

Johansen KK, White LR, Farrer MJ, Aasly JO.

Parkinsonism Relat Disord. 2011 Aug;17(7):528-32. doi: 10.1016/j.parkreldis.2011.04.014. Epub 2011 Jun 8.

PMID:
21641848
12.

A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations.

Lohmann E, Leclere L, De Anna F, Lesage S, Dubois B, Agid Y, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group.

Parkinsonism Relat Disord. 2009 May;15(4):273-6. doi: 10.1016/j.parkreldis.2008.06.008. Epub 2008 Aug 21.

PMID:
18718805
13.

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.

Yahalom G, Kaplan N, Vituri A, Cohen OS, Inzelberg R, Kozlova E, Korczyn AD, Rosset S, Friedman E, Hassin-Baer S.

Parkinsonism Relat Disord. 2012 Nov;18(9):1039-41. doi: 10.1016/j.parkreldis.2012.05.014. Epub 2012 Jun 13.

PMID:
22703868
14.

REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers.

Saunders-Pullman R, Alcalay RN, Mirelman A, Wang C, Luciano MS, Ortega RA, Glickman A, Raymond D, Mejia-Santana H, Doan N, Johannes B, Yasinovsky K, Ozelius L, Clark L, Orr-Utreger A, Marder K, Giladi N, Bressman SB; AJ LRRK2 Consortium.

Mov Disord. 2015 Nov;30(13):1834-9. doi: 10.1002/mds.26413. Epub 2015 Sep 14.

15.

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?

Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N.

Neurology. 2007 Oct 16;69(16):1595-602.

PMID:
17938369
16.

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, Inzelberg R, Hassin-Baer S, Friedman E, Ruiz-Martinez J, Marti-Masso JF, Orr-Urtreger A, Bressman S, Saunders-Pullman R.

JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973.

17.

The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.

Gatto EM, Parisi V, Converso DP, Poderoso JJ, Carreras MC, Martí-Massó JF, Paisán-Ruiz C.

Neurosci Lett. 2013 Mar 14;537:1-5. doi: 10.1016/j.neulet.2013.01.011. Epub 2013 Jan 20.

PMID:
23340200
18.

Substantia nigra hyperechogenicity with LRRK2 G2019S mutations.

Brüggemann N, Hagenah J, Stanley K, Klein C, Wang C, Raymond D, Ozelius L, Bressman S, Saunders-Pullman R.

Mov Disord. 2011 Apr;26(5):885-8. doi: 10.1002/mds.23644. Epub 2011 Feb 10.

19.

Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.

Mirelman A, Alcalay RN, Saunders-Pullman R, Yasinovsky K, Thaler A, Gurevich T, Mejia-Santana H, Raymond D, Gana-Weisz M, Bar-Shira A, Ozelius L, Clark L, Orr-Urtreger A, Bressman S, Marder K, Giladi N; LRRK2 AJ consortium.

Mov Disord. 2015 Jun;30(7):981-6. doi: 10.1002/mds.26213. Epub 2015 Mar 21.

20.

Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.

Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M-, Rosado L, Orbe Reilly M, Ruiz D, Ross B, Verbitsky M, Kisselev S, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Payami H, Molho E, Factor S, Ottman R, Clark LN, Marder K.

Neurology. 2012 May 1;78(18):1434-40. doi: 10.1212/WNL.0b013e318253d54b. Epub 2012 Mar 21.

Supplemental Content

Support Center